Search

everythinglearnresearchcommunity

for

Search:↓

Hair ages due to genetics and environmental factors, leading to graying and thinning, with treatments available for some conditions.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

To diagnose hair loss, use a systematic approach including history, exams, and tests.

The study found that diseases can be grouped by symptoms and that the accuracy of predicting disease-related genes varies with the data source.

Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.

The article concludes that while we understand a lot about how melanocytes age and how this can prevent cancer, there are still unanswered questions about certain pathways and genes involved.

Hair mineral analysis might help diagnose diseases early, but standard methods are needed.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Minoxidil and finasteride are effective for male hair loss, minoxidil for female hair loss, and various treatments like corticosteroids work for alopecia areata; treatment should be tailored to the individual.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

The representation of skin conditions in medical reviews partly matches their real-world impact.

Advanced human skin models improve drug development and could replace animal testing.

Trichoscopy is a quick, cost-effective tool for diagnosing different hair loss conditions.

The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Both mouse and rat models are effective for testing alopecia areata treatments.

Cyclosporin is effective for treating skin conditions in small animals, but requires careful dosing and monitoring for side effects.

Tattooing helps treat skin conditions, reconstruct nipple-areola, mark radiation fields, and locate lesions.

The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.

Nearly half of children with primary immunodeficiency disorders showed skin problems, often as the first sign of their condition.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.

HIV can cause unusual and severe skin problems that are hard to treat.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.